Krensavage Asset Management LLC Raises Stake in Abbott Laboratories $ABT

Krensavage Asset Management LLC boosted its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 3,900.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 200,000 shares of the healthcare product maker's stock after buying an additional 195,000 shares during the quarter. Abbott Laboratories makes up about 6.9% of Krensavage Asset Management LLC's investment portfolio, making the stock its 6th largest holding. Krensavage Asset Management LLC's holdings in Abbott Laboratories were worth $18,148,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. MidAtlantic Capital Management Inc. bought a new position in shares of Abbott Laboratories in the fourth quarter worth about $25,000. Cornerstone Financial Management LLC purchased a new stake in Abbott Laboratories in the 4th quarter worth $25,000. Purpose Unlimited Inc. purchased a new stake in Abbott Laboratories in the 4th quarter worth $25,000. Portfolio Resources Advisor Group Inc. bought a new stake in Abbott Laboratories during the fourth quarter valued at about $26,000. Finally, Abound Financial LLC purchased a new position in shares of Abbott Laboratories in the fourth quarter valued at about $26,000. 75.18% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on ABT. TD Cowen reissued a "buy" rating and set a $135.00 target price on shares of Abbott Laboratories in a research note on Tuesday. Piper Sandler reaffirmed an "overweight" rating and set a $118.00 price objective (up from $115.00) on shares of Abbott Laboratories in a report on Friday, July 17th. Bank of America lowered their target price on shares of Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. BTIG Research upped their target price on shares of Abbott Laboratories from $131.00 to $134.00 and gave the stock a "buy" rating in a research report on Friday, July 17th. Finally, UBS Group reduced their price target on shares of Abbott Laboratories from $135.00 to $125.00 and set a "buy" rating on the stock in a report on Tuesday, July 28th. Three research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $119.50.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: The FDA approved Abbott’s TactiFlex Duo Ablation Catheter, Sensor Enabled, for treating challenging cases of atrial fibrillation. The catheter combines pulsed-field ablation (PFA) and radiofrequency (RF) energy, giving physicians greater flexibility and expanding Abbott’s cardiac rhythm-management portfolio. The device previously received a European CE mark in January 2026, and U.S. approval could support broader adoption and future revenue growth. Abbott’s dual ablation catheter lands FDA approval
• Positive Sentiment: TD Cowen reaffirmed its “buy” rating on Abbott and maintained a $135 price target, indicating substantial potential upside from recent trading levels. The endorsement suggests the firm views Abbott’s product pipeline and long-term fundamentals favorably. TD Cowen reaffirms Abbott buy rating
• Neutral Sentiment: A comparison of Abbott and Envista focuses on which medical-products stock offers better value. Abbott’s established business and growth prospects remain attractive, but its valuation may make it less compelling to investors specifically seeking undervalued shares. NVST or ABT: Which Is the Better Value Stock Right Now?
• Neutral Sentiment: Abbott was highlighted as a potential defensive “Dividend King,” supported by a 54-year dividend-growth streak and healthcare-related catalysts. This may appeal to income-focused investors, although the article is general commentary rather than a new company announcement. If a Stock Market Crash Is Coming, Investors Will Want to Own This Dividend King
• Negative Sentiment: Abbott recently underperformed the broader market in a prior session, reflecting near-term selling pressure. The decline appears market- or sentiment-driven rather than tied to a deterioration in the company’s fundamentals, but it may be tempering the immediate reaction to the FDA news. Here’s Why Abbott Fell More Than the Broader Market

Abbott Laboratories Stock Performance

NYSE ABT opened at $105.29 on Thursday. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $137.49. The business has a 50 day simple moving average of $105.30 and a two-hundred day simple moving average of $99.90. The stock has a market capitalization of $182.19 billion, a PE ratio of 34.07, a P/E/G ratio of 1.96 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. During the same quarter in the prior year, the firm earned $1.26 earnings per share. Abbott Laboratories's revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, research analysts predict that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were given a $0.63 dividend. The ex-dividend date was Wednesday, July 15th. This represents a $2.52 annualized dividend and a yield of 2.4%. Abbott Laboratories's dividend payout ratio (DPR) is currently 81.55%.

About Abbott Laboratories

Abbott Laboratories NYSE: ABT is a global healthcare company that develops, manufactures and sells medical products and technologies. Its operations span four principal areas: medical devices, diagnostics, established pharmaceutical products and nutrition. Abbott serves healthcare providers, institutions and consumers in markets around the world.

The company's medical device portfolio includes products for cardiovascular care, diabetes management and other specialties. Its diagnostics business provides laboratory systems, tests and point-of-care solutions, while its nutrition products include infant, child and adult nutritional offerings sold under brands such as Similac, Ensure and Pedialyte.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.